Top Midday Gainers

MT Newswires Live12-09

Top Wealth Group (TWG) disclosed late Friday a "positive" outlook for the financial year ending Dec. 31, anticipating net profits of not less than $4 million, rebounding from a $2 million loss a year ago.

Shares of the company more than doubled as intraday trading volume catapulted to over 16.5 million from a daily average of about 249,000.

Wave Life Sciences (WVE) said Monday that interim data from its phase 1 trial of WVE-007, an obesity treatment, showed improvements in body composition.

The weight loss was similar to GLP-1, but without muscle loss, the company added.

Shares of the company soared 140% as intraday trading volume surged to over 119 million from a daily average of roughly 2.6 million.

Structure Therapeutics (GPCR) disclosed on Monday that its obesity drug candidate aleniglipron achieved statistical significance in the phase 2b trial's primary and key secondary endpoints.

Shares of the company surged 99% as intraday trading volume climbed to more than 16.1 million from a daily average of about 1.1 million.

Price: 19.63, Change: +13.62, Percent Change: +226.62

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590368764?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 03:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590368764","market":"fut","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TWG\">Top Wealth</a> Group (TWG) disclosed late Friday a \"positive\" outlook for the financial year ending Dec. 31, anticipating net profits of not less than $4 million, rebounding from a $2 million loss a year ago.</p><p>Shares of the company more than doubled as intraday trading volume catapulted to over 16.5 million from a daily average of about 249,000.</p><p><a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) said Monday that interim data from its phase 1 trial of WVE-007, an obesity treatment, showed improvements in body composition.</p><p>The weight loss was similar to GLP-1, but without muscle loss, the company added.</p><p>Shares of the company soared 140% as intraday trading volume surged to over 119 million from a daily average of roughly 2.6 million.</p><p>Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GPCR) disclosed on Monday that its obesity drug candidate aleniglipron achieved statistical significance in the phase 2b trial's primary and key secondary endpoints.</p><p>Shares of the company surged 99% as intraday trading volume climbed to more than 16.1 million from a daily average of about 1.1 million.</p><p>Price: 19.63, Change: +13.62, Percent Change: +226.62</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 03:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TWG\">Top Wealth</a> Group (TWG) disclosed late Friday a \"positive\" outlook for the financial year ending Dec. 31, anticipating net profits of not less than $4 million, rebounding from a $2 million loss a year ago.</p><p>Shares of the company more than doubled as intraday trading volume catapulted to over 16.5 million from a daily average of about 249,000.</p><p><a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) said Monday that interim data from its phase 1 trial of WVE-007, an obesity treatment, showed improvements in body composition.</p><p>The weight loss was similar to GLP-1, but without muscle loss, the company added.</p><p>Shares of the company soared 140% as intraday trading volume surged to over 119 million from a daily average of roughly 2.6 million.</p><p>Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GPCR) disclosed on Monday that its obesity drug candidate aleniglipron achieved statistical significance in the phase 2b trial's primary and key secondary endpoints.</p><p>Shares of the company surged 99% as intraday trading volume climbed to more than 16.1 million from a daily average of about 1.1 million.</p><p>Price: 19.63, Change: +13.62, Percent Change: +226.62</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590368764","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590368764","pubTimestamp":1765222388,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Top Wealth Group  disclosed late Friday a \"positive\" outlook for the financial year ending Dec. 31, anticipating net profits of not less than $4 million, rebounding from a $2 million loss a year ago.Shares of the company more than doubled as intraday trading volume catapulted to over 16.5 million from a daily average of about 249,000.Wave Life Sciences  said Monday that interim data from its phase 1 trial of WVE-007, an obesity treatment, showed improvements in body composition.The weight loss was similar to GLP-1, but without muscle loss, the company added.Shares of the company soared 140% as intraday trading volume surged to over 119 million from a daily average of roughly 2.6 million.Structure Therapeutics  disclosed on Monday that its obesity drug candidate aleniglipron achieved statistical significance in the phase 2b trial's primary and key secondary endpoints.Shares of the company surged 99% as intraday trading volume climbed to more than 16.1 million from a daily average of abo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd","TWG":"富原集团","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4212":"包装食品与肉类","BK4599":"减肥药","BK4007":"制药"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":1,"TWG":1,"GPCR":1},"content_text":"Top Wealth Group (TWG) disclosed late Friday a \"positive\" outlook for the financial year ending Dec. 31, anticipating net profits of not less than $4 million, rebounding from a $2 million loss a year ago.Shares of the company more than doubled as intraday trading volume catapulted to over 16.5 million from a daily average of about 249,000.Wave Life Sciences (WVE) said Monday that interim data from its phase 1 trial of WVE-007, an obesity treatment, showed improvements in body composition.The weight loss was similar to GLP-1, but without muscle loss, the company added.Shares of the company soared 140% as intraday trading volume surged to over 119 million from a daily average of roughly 2.6 million.Structure Therapeutics (GPCR) disclosed on Monday that its obesity drug candidate aleniglipron achieved statistical significance in the phase 2b trial's primary and key secondary endpoints.Shares of the company surged 99% as intraday trading volume climbed to more than 16.1 million from a daily average of about 1.1 million.Price: 19.63, Change: +13.62, Percent Change: +226.62","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590368764","isCrawlerRequest":true}